About Amryt Pharma
Amryt Pharma is a Healthcare company based in Dublin (Ireland) founded in 2015, and was acquired by Chiesi Pharmaceuticals in January 2023. Therapeutics for rare dermatological and orphan diseases are developed. Amryt Pharma has completed 4 acquisitions, including Aegerion, Birken and Chiasma. Its chief executive, as recorded, is Joe Wiley. Amryt Pharma offers products and services including Juxtapid / Lojuxta, Myalept / Myalepta, and Mycapssa. Its focus areas include Life Sciences, Rare Diseases, Drugs and Dermatological Diseases. Its legal entity is Amryt Pharma plc.
Company details
Amryt Pharma was founded in 2015 and is headquartered in Dublin, Ireland. Therapeutics for rare and orphan diseases, particularly in dermatology, are developed by the company. Treatments such as Juxtapid for homozygous familial hypercholesterolemia and Myalepta for lipodystrophy have been created. Products addressing hereditary skin disorders like epidermolysis bullosa are also included in its portfolio. Operations center on pharmaceutical research and development for underserved patient populations.
- Headquarters Dublin, Ireland
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website amrytpharma.com
- Social LinkedIn X Facebook Instagram
- Acquired by Chiesi Pharmaceuticals (Jan 2023)
- Legal Name Amryt Pharma Plc
- Annual Revenue$239.89 M (USD)51as on Dec 31, 2015
- Net Profit-$73.34 M (USD)-86as on Dec 31, 2015
- EBITDA-$45.19 M (USD)-69as on Dec 31, 2015
- Latest Funding Round$40M (USD), Post-IPO
Dec 2020
- InvestorsEuropean Investment Bank
& 7 more
- Investments & AcquisitionsAegerion
& 3 more
- Acquired byChiesi Pharmaceuticals
(Jan 2023)
Products & Services of Amryt Pharma
Amryt Pharma offers a comprehensive portfolio of products and services, including Juxtapid / Lojuxta, Myalept / Myalepta, and Mycapssa.
Treatment for homozygous familial hypercholesterolaemia and related conditions.
Therapy for lipodystrophy and metabolic disorders.
Management for acromegaly and hormonal imbalances.
Funding Insights of Amryt Pharma
- Total Rounds 5
- Last Round Post-IPO — $40M
- First Round $14.2M
(Apr 2016)
- Investors Count 7
All 5 funding rounds of Amryt Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $40M | Post-IPO | – | – | |
| Sep 2019 | $60M | Post-IPO | – | – | – |
| Dec 2018 | $9.56M | Grant | – | – | |
| Dec 2016 | $21.23M | Debt – Venture | – | – | |
| Apr 2016 | $14.2M | Post-IPO | – | – | – |
8 investors in total: 8 institutional.
Investors in Amryt Pharma
Amryt Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Chiesi Pharmaceuticals and Government.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
StonePine Capital Partners is focused on private equity investments. | stonepine-capital.com | |||
| aquilocapitalmanagement.com | ||||
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Funds-based investment management services are provided to clients. | 2010 | amatiglobal.com | Edinburgh, United Kingdom | |
| highbridge.com | ||||
Statistics, budgetary information, and government services are provided. | 2000 | gov.ie | Dublin, Ireland | |
Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas | 1935 | chiesi.com | Parma, Italy |
Investor details for Amryt Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amryt Pharma
29 people are tracked at Amryt Pharma (11 in leadership, 18 in team).
| Name | Role | Group |
|---|---|---|
Joe Wiley | CEO | Leadership |
Niall Goulding | Head Of Tax | Leadership |
Shir Fuchs Orenbach | Senior Director, Global Clinical Research Physician At Amryt | Leadership |
Orla Carroll | Associate Director, Regulatory Affairs Cmc, Lead, Biologics Portfolio | Leadership |
Derval O’Carroll | Head of Regulatory Affairs | Leadership |
Michael Farrell | Director Of Commercial Operations | Leadership |
Tanuja Somani | CMO Quality Manager | Leadership |
Julie Eastwood | Head Of Human Resources | Leadership |
Michael Inglis | Head Of Manufacturing Sciences Analytical Technology (msat) | Leadership |
Phillip Eichorn | Global Head Of Drug Safety | Leadership |
Clare Cushen | Head Of Medical Affairs, Europe | Leadership |
Shivani Choudhary | Senior Manager Regulatory Affairs | Team |
Simone Klusch | Clinical Project Manager | Team |
Siobhán Moyna | Senior Regulatory Affairs Manager EMEA | Team |
Lori Reiman | Strategic Account Lead | Team |
Michelle Buckley | Deputy QPPV / Pharmacovigilance Manager | Team |
Sean Hanaway | Qualified Person (qp)/cmc Quality Manager | Team |
Ken A. | Regional Rare Disease Specialist | Regional Marketing Liaison | Team |
Dorota Witkowska | HR & Payroll Manager | Team |
Sharon Goffer-Aviram | Office Manager & HR Admin | Team |
9 more people are available in the full profile.
Complete people profiles for Amryt Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amryt Pharma
Amryt Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Aegerion, Birken and Chiasma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for rare diseases are developed via oral platform technology. | chiasma.com | Needham, United States | 2001 | May 2021 | •••• | |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed. | aegerion.com | Cambridge, United States | 2005 | May 2019 | $85M | |
Somatostatin analogue peptides are developed for rare neuroendocrine diseases. | sompharmaceuticals.com | Epalinges, Switzerland | 2012 | Apr 2016 | •••• | |
German, clinical-stage biopharma developing botanical-origin extract for wound healing | birken.eu | 2000 | Mar 2016 | •••• |
Complete acquisition details for Amryt Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Amryt Pharma
9 dated milestones of Amryt Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Amryt Pharma is founded.
- Acquisition Acquires Birken.
- Acquisition Acquires Sompharmaceuticals.
- Funding First funding round of $14.2M.
- Acquisition Acquires Aegerion.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $40.0M.
- Acquisition Acquires Chiasma.
- Exit Acquired by Chiesi Pharmaceuticals.
Web traffic of Amryt Pharma
- Global rank#12,044,056
among all websites
- Category rank#8,203
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.6
- Average visit53 sec
- DevicesDesktop 30% · Mobile 70%
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amryt Pharma
Complete news archive for Amryt Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amryt Pharma
Amryt Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Amryt Pharma is headquartered in Dublin, Ireland.
Joe Wiley is the CEO of Amryt Pharma, as recorded in our data.
Annual revenue of Amryt Pharma is $239.89M as on Dec 31, 2015.
Amryt Pharma was founded in 2015 and is headquartered in Dublin, Ireland. Therapeutics for rare and orphan diseases, particularly in dermatology, are developed by the company. Treatments such as Juxtapid for homozygous familial hypercholesterolemia and Myalepta for lipodystrophy have been created. Products addressing hereditary skin disorders like epidermolysis bullosa are also included in its portfolio. Operations center on pharmaceutical research and development for underserved patient populations.
Amryt Pharma offers Juxtapid / Lojuxta, Myalept / Myalepta, and Mycapssa.
Amryt Pharma has 8 investors. Key investors include European Investment Bank, Chiesi Pharmaceuticals, Government, Amati Global Investors, and StonePine Capital Partners.
Amryt Pharma operates through Amryt Pharma Plc.
Yes. Amryt Pharma was acquired by Chiesi Pharmaceuticals in January 2023.